Claims for Patent: 7,381,560

Summary for Patent: 7,381,560

Title:	Expression and use of anti-CD20 antibodies
Abstract:	Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.
Inventor(s):	Anderson; Darrell R. (Escondido, CA), Hanna; Nabil (Rancho Santa Fe, CA), Newman; Roland A. (San Diego, CA), Reff; Mitchell E. (San Diego, CA), Rastetter; William H. (Rancho Santa Fe, CA)
Assignee:	Biogen Idec Inc. (Cambridge, MA)
Application Number:	09/911,692
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,381,560
Patent Claims:	1. A host cell comprising nucleic acid sequences encoding the light chain and the heavy chain of an immunologically active chimeric anti-CD20 antibody, wherein the sequence encoding the light chain comprises a nucleotide sequence encoding amino acid residues 23 to 128 of SEQ ID NO: 4, and the sequence encoding the heavy chain comprises a nucleotide sequence encoding amino acid residues 20 to 140 of SEQ ID NO: 6, wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody. 2. The host cell of claim 1 wherein the sequence encoding the light chain further comprises a nucleotide sequence encoding a human kappa light chain constant region, and the sequence encoding the heavy chain further comprises a nucleotide sequence encoding a human gamma 1 heavy chain constant region. 3. A method of making a purified antibody comprising expressing the light and heavy chains encoded by the nucleic acid sequences in the host cell of claim 1 and purifying the antibody produced by the host cell. 4. The method of claim 3 further comprising combining the purified antibody with a pharmaceutically acceptable buffer. 5. The method of claim 3 further comprising combining the purified antibody with a pharmaceutical carrier. 6. The host cell of claim 1, wherein the host cell comprises an expression vector or separate expression vectors comprising the nucleic acid sequences encoding the light chain and the heavy chain. 7. The host cell of claim 1, wherein the host cell comprises an expression plasmid or separate expression plasmids comprising the nucleic acid sequences encoding the light chain and the heavy chain. 8. The host cell of claim 1 which is a mammalian cell. 9. The host cell of claim 1 which is a Chinese Hamster Ovary (CHO) cell. 10. The host cell of claim 1 which is an SP2/0 cell.

Details for Patent 7,381,560

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Acrotech Biopharma Llc	ZEVALIN	ibritumomab tiuxetan	Injection	125019	02/19/2002		2012-11-13

International Patent Family for US Patent 7,381,560

Country	Patent Number	Estimated Expiration
Austria	139900
Austria	196606
Austria	421335
Austria	431158
Australia	5603294
Australia	688743